Transcode Therapeutics, Inc. Logo

Transcode Therapeutics, Inc.

Develops targeted RNA therapies for metastatic cancer using a proprietary nanoparticle delivery platform.

RNAZ | US

Overview

Corporate Details

ISIN(s):
US89357L1052
LEI:
Country:
United States of America
Address:
6 LIBERTY SQUARE, 2109 BOSTON
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Transcode Therapeutics, Inc. is a clinical-stage oncology company focused on developing targeted therapies for metastatic disease. The company's lead therapeutic candidate, TTX-MC138, is designed to inhibit microRNA-10b, a key regulator of metastasis. Transcode utilizes its proprietary TTX drug delivery platform, which employs tunable iron oxide nanoparticles to deliver RNA-based therapeutics specifically to cancer cells, addressing a significant challenge in the field. This platform technology has demonstrated broad potential in pre-clinical models across numerous cancer types, including breast, pancreatic, and ovarian cancer. The company aims to eradicate metastatic tumor cells that have spread from the primary tumor. Transcode recently acquired Polynoma LLC to enhance its immuno-oncology and metastatic prevention capabilities.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Transcode Therapeutics, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Transcode Therapeutics, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Transcode Therapeutics, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

CYTOKINETICS INC Logo
Late-stage biopharma developing muscle-modulating drugs for heart and neuromuscular diseases.
United States of America
CYTK
CytoMed Therapeutics Ltd Logo
Develops off-the-shelf cell immunotherapies using γδ T cells & NK cells for cancer treatment.
United States of America
GDTC
CytomX Therapeutics, Inc. Logo
Develops tumor-activated antibody therapeutics for more targeted, less toxic cancer treatments.
United States of America
CTMX
Daebonglsco.,Ltd Logo
Develops raw materials and APIs for the personal care, pharmaceutical, and food industries.
South Korea
078140
DaehanPharmaceutical Logo
Develops and manufactures pharmaceuticals and health foods for human and animal markets worldwide.
South Korea
023910
Daesung Microbiological Labs. Co. Ltd Logo
Researches and manufactures veterinary vaccines and medicines for livestock, fish, and canines.
South Korea
036480
DAEWOONG PHARMA Logo
A global R&D partner for drug development, manufacturing, and commercialization services.
South Korea
069620
DAIICHI SANKYO COMPANY, LIMITED Logo
A global pharmaceutical firm developing novel therapies with a focus on oncology and ADCs.
Japan
4568
Daito Pharmaceutical Co., Ltd. Logo
Manufactures APIs, generic drugs, and health foods; provides contract manufacturing services.
Japan
4577
Dare Bioscience, Inc. Logo
Advancing innovative therapies for women's health in contraception, fertility, and sexual health.
United States of America
DARE

Talk to a Data Expert

Have a question? We'll get back to you promptly.